Navigation Links
As Predicted: Chronic Virus Found Living in Tumors of the Prostate
Date:9/21/2009

ROCHESTER, N.Y., Sept. 21 /PRNewswire/ -- According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

More and more studies find chronic viruses living in tumors, exactly as predicted by Dr. Hanan Polansky in his highly acclaimed 2003 "purple book." According to Dr. Polansky, a chronic virus is a genetic parasite. In high concentrations, the virus "starves" certain human genes and forces them to behave as if they have been mutated, leading to cancer and other diseases.

Think of the nucleus inside the cell as a field with many flowers. To bear fruit, the flowers need pollination by certain bees. Now think of a virus as another flower that migrated into the field. The viral flower also attracts the bees, however with much higher efficiency (stronger scent?). What happens to the production of fruit by the local flowers? It declines. And since many animals are dependent on this fruit, the entire ecosystem is affected. The "starved" human genes stop bearing their fruit, or proteins. They behave as if they've been mutated. (They were not, but to a puzzled scientist they look like they've been mutated!) And without the needed proteins, the cell stops functioning properly, a condition we call disease.

The Starved Gene is a fundamental discovery. It applies to many viruses, many human genes, and many diseases. This discovery inspired scientists at polyDNA to develop a broad-range, all-natural nutritional supplement that targets viruses. To develop the antiviral supplement, they used their signature process. They scanned the scientific literature, analyzed thousands of papers using a proprietary bioinformatics-based computer program, and identified the most effective and safe antiviral natural ingredients. These ingredients were combined to form Gene-Eden, a supplement that targets viruses such as the flu virus, Epstein Barr Virus (EBV), Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), Varicella Zoster Virus(VZV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Papillomavirus (HPV).

For more information on Gene-Eden, visit http://www.gene-eden.com. To order Gene-Eden, visit http://www.Amazon.com.

About Us:

The Center for the Biology of Chronic Disease (http://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c)3 of the IRS tax code. The center's mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases.

To receive our newsletter, please send the contact below an email with "Please add" in the subject. The newsletter includes announcements and explanations of recent scientific discoveries regarding the biology, prevention, and treatment of chronic diseases in everyday terms.

    Contact:

    Tal Davidson
    Phone: 585-200-5546
    Email: tdavidson@cbcd.net

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE The Center for the Biology of Chronic Disease
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
3. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
4. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
9. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
10. Move to AMITIZA Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017   Sienna Biopharmaceuticals, Inc. , ... today announced that Richard Peterson will join ... Peterson, who brings more than two decades ... , who is retiring at the end of April ... capacity. Peterson joins Sienna from Novan, Inc., where he ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Global Markets" report to their offering. ... The Global Market ... Billion in 2016 at a CAGR of 8.9%, ... and non-energetic bioproducts into seven major product segments: bio-derived chemicals, ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... , March 23, 2017 According to ... products and derivatives market is fragmented due to the presence of a ... as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each ... three companies, collectively, held more than 76% of this market in ... As of ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):